Potent Rho kinase (ROCK) inhibitor (IC50
values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively). Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50
= 35 nM); lowers blood pressure in a rat model of hypertension.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline.
Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
Doe et al.
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger et al.
The citations listed below are publications that use Tocris products. Selected citations for GSK 269962 include:
Showing Results 1 - 1 of 1